3-Methyl-2-(4-substituted phenyl)-4,5-dihydronaphtho[1,2-c]-pyrazoles: Synthesis and in-vitro biological evaluation as antitumour agents

Archiv der Pharmazie

Volumn 341, Issue 3, 2008, Pages 181-190

  Al Saadi, Mohamed S ^a   Rostom, Sherif A F ^a   Faidallah, Hassan M ^a  

^a King Abdulaziz University   (Saudi Arabia)

Author keywords

Antitumour activity; Cytotoxicity; Dihydronaphtho 1,2 c pyrazoles; Thiazinanes; Thiazoles

Indexed keywords

1,3 THIAZINAN 4 ONE; 1,3 THIAZINAN 5 ONE; 3 BENZYL 2 [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYLIMINO] 1,3 THIAZINAN 5 ONE; 3 METHYL 2 (4 SULFANYLPHENYL) 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOLE; 3,6 DIPHENYL 5 [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYLIMINO] 2 METHYL 3,3A,5,6 TETRAHYDRO 2H PYRAZOLO[3,4 D]THIAZOLE; 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOLE DERIVATIVE; 5 [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYLIMINO] 3 PHENYL 7H THIAZOLO[4,3 C][1,2,4]TRIAZOLE; 5 BENZYLIDENE 2 [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYLIMINO] 3 PHENYLTHIAZOLIDIN 4 ONE; [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYL]THIOUREA DERIVATIVE; [4 (3 METHYL 4,5 DIHYDRONAPHTHO[1,2 C]PYRAZOL 2 YL)BENZENESULFONYL]UREA DERIVATIVE; ANTINEOPLASTIC AGENT; SULFONE DERIVATIVE; SULFONYLTHIOUREIDO DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; PYRAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL STRAIN MCF 7; CELL VIABILITY; CHEMICAL REACTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LC 50; PARAMETER; PHARMACOPHORE; POLYMERIZATION; PRIORITY JOURNAL; REACTION ANALYSIS; TECHNIQUE; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; FEMALE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 44649188523     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700178     Document Type: Article

References (38)

1. M. F. Braña, A. Ramos, Curr. Med. Chem. Anticancer Agents 2001, 1, 237-255.
2. M. T. Cocco, C. Congiu, V. Onnis, Eur. J. Med. Chem. 2000, 35, 545-552.
3. J. C. Medina, B. Shan, H. Beckmann, R. P. Farrell, et al., Bioorg. Med. Chem. Lett. 1998, 8, 2653-2656.
4. C. W. Lee, D. H. Hong, S. B. Han, S.-H. Jong, et al., Biochem. Pharmacol. 2002, 64, 473-480.
5. S.-H. Kwak, S.-C. Bang, H.-H. Seo, H.-R. Shin, et al., Arch. Pharm. Res. 2006, 29, 721-727.
6. L. Hu, Z.-R. Li, Y. Li, J. Qu, et al., J. Med. Chem. 2006, 49, 6273-6282.
7. Z. Brzozowski, F. Saczewski, J. Slawinski, P. J. Bednarski, et al., Bioorg. Med. Chem. 2007, 15, 2560-2572.
8. J. J. Howbert, C. S. Grossman, T. A. Crowell, B. J. Rieder, et al., J. Med. Chem. 1990, 33, 2393-2407.
9. A. Mastrolorenzo, A. Scozzafava, C. T. Supuran, Eur. J. Pharm. Sci. 2000, 11, 325-332.
10. S. Khelili, P. Lebrun, P. de Tullio, B. Pirotte, Bioorg. Med. Chem. 2006, 14, 3530-3534.
11. A. Scozzafava, C. T. Supuran, J. Enzyme Inhib. 1999, 14, 343-363.
12. A. Scozzafava, C. T. Supuran, Eur. J. Pharm. Sci. 2000, 10, 29-41.
13. G. De Simone, R. M. Vitale, A. Di Fiore, C. Pedone, et al., J. Med. Chem. 2006, 49, 5544-5551.
14. H. Foks, D. Pancechowska-Ksepko, A. Kedzia, Z. Zwolska, et al., Farmaco 2005, 60, 513-517.
15. Z. Dardari, M. Lemrani, A. Sebban, A. Bahloul, et al., Arch. Pharm. Chem. Life Sci. 2006, 33, 291-298.
16. A. M. Gilbert, A. Failli, J. Shumsky, Y. Yang, et al., J. Med. Chem. 2006, 49, 6027-6036.
17. P. Rathelot, N. Azas, H. El-Kashef, F. Delmas, et al., Eur. J. Med. Chem. 2002, 37, 671-679.
18. A. M. R. Bernardino, A. O. Gomes, K. S. Charret, A. C. C. Freitas, et al., Eur. J. Med. Chem. 2006, 41, 80-87.
19. S. B. Katiyar, K. Srivastava, S. K. Purib, P. M. S. Chauhana, Bioorg. Med. Chem. Lett. 2005, 15, 4957-4960.
20. O. Moukha-Chafiq, M. L. Taha, H. B. Lazrek, J.-J. Vasseur, et al., Farmaco 2002, 57, 27-32.
21. S. H. Allen, B. A. Johns, K. S. Gudmundsson, G. A. Freeman, et al., Bioorg. Med. Chem. 2006, 14, 944-954.
22. P. G. Baraldi, I. Beria, P. Cozzi, C. Geroni, et al., Bioorg. Med. Chem. 2004, 12, 3911-3921.
23. G. Daidone, D. Raffa, B. Maggio, M. V. Raimondi, et al., Eur. J. Med. Chem. 2004, 39, 219-224.
24. A. Gopalsamy, H. Yang, J. W. Ellingboe, H. Tsou, et al., Bioorg. Med. Chem. Lett. 2005, 15, 1591-1594.
25. M. T. Cocco, C. Congiu, V. Lilliu, V. Onnis, Arch. Pharm. Chem. Life Sci. 2006, 339, 7-13.
26. H. T. Y. Fahmy, S. A. F. Rostom, A. A. Bekhit, Arch. Pharm. Pharm. Med. Chem. 2002, 335, 213-222.
27. H. T. Y. Fahmy, S. A. F. Rostom, M. N. S. Saudi, J. K. D. Zjawiony, J. Robins, Arch. Pharm. Pharm. Med. Chem. 2003, 336, 216-225.
28. A. A. Bekhit, H. T. Y. Fahmy, S. A. F. Rostom, A. M. Baraka, Eur. J. Med. Chem. 2003, 38, 27-36.
29. S. A. F. Rostom, M. A. Shalaby, M. A. El-Demellawy, Eur. J. Med. Chem. 2003, 38, 959-974.
30. S. A. F. Rostom, H. T. Y. Fahmy, M. N. S. Saudi, Sci. Pharm. 2003, 71, 57-74.
31. M. S. M. Al-Saadi, S. A. F. Rostom, H. M. Faid Allah, Saudi Pharm. J. 2005, 13, 89-96.
32. S. A. F. Rostom, Bioorg. Med. Chem. 2006, 14, 6475-6485.
33. M. R. Grever, S. A. Schepartz, B. A. Chabner, Seminars Oncol. 1992, 19, 622-638.
34. M. R. Boyd, K. D. Paull, Drug Rev. Res. 1995, 34, 91-109.
35. A. Monks, D. Scudiero, P. R. Skehan, K. Shoemaker, et al., J. Natl. Cancer Inst. 1991, 83, 757-766.
36. W. Li, M. Lam, D. Choy, A. Brikeland, et al., Toxicol In Vitro 2006, 20, 669-676.
37. F. Denizot, R. Lang, J. Immunol. Methods 1986, 22, 271-277.
38. E. M. Acton, V. L. Narayanan, P. A. Risbood, R. H. Shoemaker, et al., J. Med. Chem. 1994, 37, 2185-2189.